Cost-Effectiveness of Early vs Delayed Belimumab Treatment for Systemic Lupus Erythematosus

20261 citationsJournal Articlegold Open Access

Authors

Sabrina Hundal · University of Calgary

J. Cappelli · McMaster University

Christopher Sjöwall · Linköping University

Mohamed Osman · University of Alberta

Zahi Touma · University Health Network

Ioannis Parodis · Karolinska University Hospital

Stephanie R. Goldberg · Mary Washington Hospital

Abstract

In this economic evaluation of early vs delayed belimumab in biologic-naive patients with active SLE, early initiation was associated with improved health outcomes and reduced costs. These findings support earlier clinical adoption and reconsideration of reimbursement criteria to reflect long-term value.

Topics & Keywords

Systemic Lupus Erythematosus Research Monoclonal and Polyclonal Antibodies Research Liver Diseases and Immunity

Publication Details

Published in: JAMA Network Open

Volume 9, Issue 2, pp. e2560167-e2560167

DOI: 10.1001/jamanetworkopen.2025.60167

Field-Weighted Citation Impact: 49.52

Command Palette

Cost-Effectiveness of Early vs Delayed Belimumab Treatment for Systemic Lupus Erythematosus

Authors

Abstract

Topics & Keywords

Publication Details